| Bioactivity | Nebacumab (HA-1A) is a monoclonal antibody that binds to lipid A portion of endotoxin. Nebacumab can be used of research of sepsis[1][2]. |
| Invitro | Nebacumab (24 μg/mL，24 小时) 在全身炎症反应综合征 (SIRS) 患者的全血中诱导产生 IL-6[2]。Nebacumab (0-100 μg/mL) 抑制外周血单核细胞产生 TNF-α、IL-1β 和 IL-6[3]。Nebacumab (1 和 100 μg/mL，14 天) 抑制内毒素对大鼠中耳上皮细胞的增殖和形态学影响[4]。 |
| In Vivo | Nebacumab (3 mg/kg，静脉注射) 降低感染了 E.coli 的小鼠的内毒素循环水平[5]。 Animal Model: |
| Name | Nebacumab |
| CAS | 138661-01-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ziegler EJ, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429-36. [2]. Yentis SM, et al. In vitro effects of HA-1A (Centoxin) on cytokine production in whole blood from intensive care unit patients. Br J Anaesth. 1994 Dec;73(6):805-11. [3]. Katsikis P, et al. Antilipid a monoclonal antibody HA-1A: immune complex clearance of endotoxin reduces TNF-alpha, IL-1 beta and IL-6 production. Cytokine. 1993 Jul;5(4):348-53. [4]. Grote JJ, et al. Effect of HA-1A monoclonal IgM antibody on endotoxin-induced proliferation of cultured rat middle ear epithelium. Ann Otol Rhinol Laryngol. 1995 Mar;104(3):226-30. [5]. Gianotti L, et al. Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies. Burns. 1996 Mar;22(2):120-4. |